Mutations in GLI1 [108] and GLI2 [109,110], and those in SUFU [111], which disrupt its binding to GLI, have been found in sporadic BCC and can lead to constitutive pathway activation. This evidence concerns the gene GLI2 and skin basal cell carcinoma.